• Akgün KM, Krishnan S, Tate J, Bryant K, Pisani MA, Lo Re V, Rentsch CT, Crothers K, Gordon KS, Justice AC, VACS project team. Delirium among people aging with and without HIV: Role of alcohol and Neurocognitively active medications. Journal of the American Geriatrics Society. 2023 Feb 14.
• Soares C, Kwok M, Boucher KA, Haji M, Echouffo-Tcheugui JB, Longenecker CT, Bloomfield GS, Ross D, Jutkowtiz E, Sullivan JL, Rudolph JL, Wu WC, Erqou S. Performance of Cardiovascular Risk Prediction Models Among People Living With HIV: A Systematic Review and Meta-analysis. JAMA cardiology. 2023 Feb 1; 8(2):139-149.
• Crothers K, Nance RM, Whitney BM, Harding BN, Heckbert SR, Budoff MJ, Mathews WC, Bamford L, Cachay ER, Eron JJ, Napravnik S, Moore RD, Keruly JC, Willig A, Burkholder G, Feinstein MJ, Saag MS, Kitahata MM, Crane HM, Delaney JAC, for CNICS. Chronic obstructive pulmonary disease and the risk for myocardial infarction by type in people with HIV. AIDS (London, England). 2023 Apr 1; 37(5):745-752.
• Sung ML, Viera A, Esserman D, Tong G, Davidson D, Aiudi S, Bailey GL, Buchanan AL, Buchelli M, Jenkins M, John B, Kolakowski J, Lame A, Murphy SM, Porter E, Simone L, Paris M, Rash CJ, Edelman EJ. Contingency Management and Pre-Exposure Prophylaxis Adherence Support Services (CoMPASS): A hybrid type 1 effectiveness-implementation study to promote HIV risk reduction among people who inject drugs. Contemporary clinical trials. 2023 Feb 1; 125:107037.
• Barry MP, Austin EJ, Bhatraju EP, Glick SN, Stekler JD, Tung EL, Hansen RN, Williams EC, Gojic AJ, Pickering EI, Tsui JI. Qualitative inquiry into perceptions of HIV pre-exposure prophylaxis among people who inject drugs living with hepatitis C in Seattle, WA, USA. Harm reduction journal. 2022 Nov 1; 19(1):121.

» View more Citations

• VA Successfully Implements Interferon-free Treatment for Hepatitis C Virus in Previously Undertreated Patient Populations
  This study examined the adoption of interferon-free treatment for hepatitis C virus (HCV) in VA to learn who received this therapy and whether the limitations of interferon-containing treatments have been overcome, including low rates of use among VA healthcare users who are African American or Hispanic, and among those with HCV-HIV co-infection. Findings showed that with the advent of interferon-...
  
  Date: March 7, 2018
• Evidence Review Identifies Modest Mortality Disparities among Racial and Ethnic Minority Groups in VA Healthcare
  To support VA’s efforts to better understand the scale and determinants of disparities in racial and ethnic mortality – and to develop interventions to reduce disparities, investigators from the VA Evidence-based Synthesis Program (ESP) Coordinating Center in Portland, OR conducted an evidence review of mortality disparities specific to VA. Findings showed that although VA’s equal access healthcar...
  
  Date: March 1, 2018
• Racial Disparities in HIV Quality of Care that May Extend to Common Comorbid Conditions
  To more fully understand patterns of racial disparities in the quality of care for persons with HIV infection, this study examined a national cohort of Veterans in care for HIV in the VA healthcare system during 2013. Findings showed that racial disparities were identified in quality of care specific to HIV infection – and in the care of common comorbid conditions. Blacks were less likely than whi...
  
  Date: September 22, 2016
• New Guidelines May Significantly Decrease Cost for Testing Immune Function in Veterans with HIV
  In 2012, the Department of Health and Human Services recommended CD4 testing in patients with HIV every 3 to 6 months – except in patients with consistently suppressed virus and sustained CD4 cell count, who could be tested every 6 to 12 months. In 2014, updated guidelines recommended that in individuals with viral suppression, CD4 testing be considered either optional or annual, depending on the ...
  
  Date: July 1, 2016
• Consequences of Notifying VA Patients about Potential Exposure to Large-Scale Adverse Events
  This study sought to determine the intended and unintended consequences of patient notification following a large-scale adverse event (LSAE) within the VA healthcare system, which systematically looks for LSAEs, tracks potentially exposed patients, and communicates with them after LSAE notification. Findings showed that more than two-thirds of potentially exposed patients returned for HCV, HBV, an...
  
  Date: May 1, 2015

» View more Publication Briefs

» View more Studies

• Telehealth Collaborative Care for Veterans with HIV Living in Rural Settings || In Progress

  Collaborative Care for Veterans with HIV Living in Rural Settings Feature Article...largest provider of care for persons with HIV in the U.S., with more than 26,000 Veterans

• HSR&D Impacts

  ...data on HIV care The VA is the single largest provider of care to HIV-infected...about HIV. This study used 1993 and 1994 data from VA's national HIV Registry

• Management Briefs eBrief-no99 --

  ...rates of end-stage renal disease in HIV should be done in the context of other...American Veterans with colon cancer, HIV, and CKD – and for Hispanics with hepatitis

• VA Video Connect to Improve Access to Multi-disciplinary Specialty Care || In Progress

  ...the effectiveness of multidisciplinary HIV care delivered via VA Video Connect...Treatment of complex conditions like HIV requires multidisciplinary care and

• HSR&D Impacts

  Exposures INFECTIOUS AGENTS VA care for HIV is at least as cost-effective as non-VA...nation's largest provider of care to HIV-infected individuals. This study examined

» View more Publications

» View more Cyberseminars

Videos

There are currently no videos for this topic.

Podcasts

There are currently no podcasts for this topic.

Other Resources

• Visit the HIV/AIDs information section of the VA's Office of Public Health website.
• Visit the Centers for Disease Control & Prevention HIV information section.
• Learn more about all VA research related to HIV on the VA Office of Research & Development’s infectious disease topic page.